Nanosphere Q2 Revenues Shoot Up 76 Percent | GenomeWeb

NEW YORK (GenomeWeb) - Nanosphere today announced after the close of the market that its first quarter revenues rose 76 percent on sales of its Verigene Gram Positive and Gram Negative Blood Culture Tests.

For the three months ended June 30, the Northbrook, Illinois-based molecular diagnostics company said it posted record-high revenues of $4.7 million, up from $2.7 million a year ago, beating the average Wall Street expectation of $4.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.